Versican Plus L4
Canine leptospirosis vaccine (inactivated)
Table of contents
Overview
This is a summary of the European public assessment report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Authorisation details
| Product details | |
|---|---|
| Name |
Versican Plus L4
|
| Agency product number |
EMEA/V/C/003680
|
| Active substance |
Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088, L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, strain MSLB 1089, L. interrogans serogroup Canicola serovar Canicola, strain MSLB 1090, L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091 (all inactivated)
|
| International non-proprietary name (INN) or common name |
Canine leptospirosis vaccine (inactivated)
|
| Species |
Dogs
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI07AB01
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Zoetis Belgium S.A.
|
| Revision |
4
|
| Date of issue of marketing authorisation valid throughout the European Union |
30/07/2014
|
| Contact address |
Rue Laid Burniat, 1 |
Product information
17/04/2019 Versican Plus L4 - EMEA/V/C/003680 - IB/0009
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Immunologicals for canidae
-
Inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia)
Therapeutic indication
Active immunisation of dogs from six weeks of age to prevent clinical signs, infection and urinary excretion caused by Leptospira serovars bratislava, canicola, grippotyphosa and icterohaemorrhagiae. Onset of immunity: Immunity has been demonstrated from 4 weeks after completion of the primary course. Duration of immunity: At least one year following the primary vaccination course.